Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bortezomib + Dexamethasone |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bortezomib | Velcade | Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov). | ||
| Dexamethasone | Adexone | Desametasone |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03110562 | Phase III | Bortezomib + Dexamethasone + Selinexor Bortezomib + Dexamethasone | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) | Completed | USA | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUT | AUS | 4 |
| NCT02136134 | Phase III | Daratumumab Bortezomib + Dexamethasone | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | Completed | USA | TUR | SWE | POL | NLD | HUN | ESP | DEU | CZE | BRA | AUS | 4 |
| NCT01919086 | Phase II | Lenalidomide Bortezomib + Dexamethasone | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma | Completed | USA | 0 |
| NCT01734928 | Phase III | Pomalidomide Bortezomib + Dexamethasone | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Completed | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | 4 |
| NCT02755597 | Phase III | Bortezomib + Dexamethasone Bortezomib + Dexamethasone + Venetoclax | A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | Completed | USA | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 5 |
| NCT01998971 | Phase I | Pomalidomide Bortezomib + Dexamethasone Melphalan Thalidomide Lenalidomide Prednisone Daratumumab Carfilzomib Diphenhydramine Montelukast | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | Completed | USA | FRA | ESP | 0 |
| NCT01323751 | Phase Ib/II | Bortezomib + Dexamethasone Ricolinostat | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma | Completed | USA | 0 |
| NCT01470131 | Phase III | Masitinib Bortezomib + Dexamethasone | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | Terminated | USA | FRA | 0 |
CKB BOOST